New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2013
08:31 EDTIMMUImmunomedics announces U.S. patent for antibody SN-38 Conjugates
Immunomedics announced the issuance of U.S. patent no. 8,617,558 for additional claims under the patent family "Camptothecin-binding moiety conjugates," and U.S. patent no. 8,617,518 with additional claims for the patent family "Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules." Patent 8,617,558 relates to our proprietary linker technology for conjugating SN-38 to the company's humanized antibodies for targeted delivery of the potent drug to the tumor. The patent will expire in December 2023. Additional patents covering the company's antibody-drug conjugates are being prosecuted in major countries worldwide.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IMMU

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use